The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1661
ISSUE1661
October 17, 2022
Adult Immunization
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Adult Immunization
October 17, 2022 (Issue: 1661)
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but...more
- N Murthy et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:229.
- COVID-19 vaccine comparison chart (online only). Med Lett Drugs Ther 2021; 63:e1.
- Influenza vaccine for 2022-2023. Med Lett Drugs Ther 2022; 64:153.
- Prevention and treatment of monkeypox. Med Lett Drugs Ther 2022; 64:137.
- Vaccines for travelers. Med Lett Drugs Ther 2018; 60:185.
- FP Havers et al. Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:77.
- VK Phadke et al. Vaccine refusal and measles outbreaks in the US. JAMA 2020; 324:1344.
- M Marlow et al. Chapter 9: Mumps. In: Manual for the Surveillance of Vaccine-Preventable Diseases. CDC. December 15, 2021. Available at: https://bit.ly/3E1icEc. Accessed September 29, 2022.
- HQ McLean et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-4):1.
- M Marin et al. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33.
- M Marin et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1.
- Shingrix – an adjuvanted, recombinant herpes zoster vaccine. Med Lett Drugs Ther 2017; 59:195.
- H Lal et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087.
- AL Cunningham et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:1019.
- In brief: Shingrix for immunocompromised adults. Med Lett Drugs Ther 2021; 63:129.
- KL Dooling et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103.
- TC Anderson et al. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80.
- FDA Safety Communication. FDA requires a warning about Guillain-Barré Syndrome (GBS) be included in the prescribing information for Shingrix. March 24, 2021. Available at: https://bit.ly/3lmyvC6. Accessed September 29, 2022.
- E Meites et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68:698.
- JE Tota et al. Anogenital human papillomavirus (HPV) infection, seroprevalence, and risk factors for HPV seropositivity among sexually active men enrolled in a global HPV vaccine trial. Clin Infect Dis 2022; 74:1247.
- Gardasil 9 – a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47.
- Two new pneumococcal vaccines – Prevnar 20 and Vaxneuvance. Med Lett Drugs Ther 2021; 63:188.
- M Kobayashi. Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. ACIP Meeting. October 20, 2021. Available at: https://bit. Ly/2YhkaOi. Accessed September 29, 2022.
- G Falkenhorst et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One 2017; 12:e0169368.
- O Ochoa-Gondar et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population age ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58:909.
- M Suzuki et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis 2017; 17:313.
- M Kobayashi et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.
- CDC. Pneumococcal vaccine timing for adults. April 1, 2022. Available at: https://bit.ly/3SjX8Nf. Accessed September 29, 2022.
- NP Nelson et al. Prevention of hepatitis A virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69 (RR-5):1.
- M Doshani et al. Recommendations of the Advisory Committee on Immunization Practices for use of hepatitis A vaccine for persons experiencing homelessness. MMWR Morb Mortal Wkly Rep 2019; 68:153.
- CDC. Viral hepatitis surveillance report – United States, 2019. May 19, 2021. Available at: https://bit.ly/3BV6V5p. Accessed September 29, 2022.
- MK Weng et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:477.
- A two-dose hepatitis B vaccine for adults (Heplisav-B). Med Lett Drugs Ther 2018; 60:17.
- A three-antigen hepatitis B vaccine (PreHevbrio). Med Lett Drugs Ther 2022; 64:73.
- S Jackson et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine 2018; 36:668.
- T Vesikari et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2021; 21:1271.
- T Vesikari et al. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw Open 2021; 4:e2128652.
- S Schillie et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67(RR-1):1.
- S Schillie et al. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep 2018; 67:455.
- HM Soeters et al. University-based outbreaks of meningococcal disease cause by serogroup B, United States, 2013-2018. Emerg Infect Dis 2019; 25:434.
- CH Bozio et al. Meningococcal disease surveillance in men who have sex with men – United States, 2015-2016. MMWR Morb Mortal Wkly Rep 2018; 67:1060.
- CDC. Meningococcal disease outbreak among gay, bisexual men in Florida 2021-22. August 8, 2022. Available at: https://bit.ly/3rkuFLm. Accessed September 29, 2022.
- MenQuadfi – a new meningococcal (A, C, W, and Y) vaccine. Med Lett Drugs Ther 2021; 63:78.
- Bexsero – a second serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:158.
- Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5.
- SA Mbaeyi et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.
- In brief: New meningococcal serogroup B vaccination recommendations. Med Lett Drugs Ther 2020; 62:191.
- HM Soeters et al. Current epidemiology and trends in invasive Haemophilus influenzae disease–United States, 2009-2015. Clin Infect Dis 2018; 67:881.
- EC Briere et al. Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-1):1.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Adult Immunization
Article code: 1661a
Article code: 1661a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.